LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

LumiThera announced positive results from its LIGHTSITE IIIB Extension Trial, showing long-term benefits of the Valeda Light Delivery System for dry AMD. The treatment, FDA-approved in November 2024, maintained vision improvement for up to 4.5 years, even after a 20-month treatment break, with a strong safety profile.